LY2228820

p38 MAP kinase (MAPK) inhibitor

More Views

From: 37 USD

Options

* Required Fields

Catalog # (Select a product)
p38 MAP kinase (MAPK) inhibitor
From: 37 USD

Overview

LY2228820 is a trisubstituted imidazole derivative and a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK) in vitro (IC₅₀ = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities (Campbell et al.). This product is supplied as the dimesylate salt of the molecule.


MAINTENANCE AND SELF-RENEWAL
· Combined with other small molecule inhibitors such as Rapamycin (Catalog #73362) and SR1 (Catalog #72342; Li et al.) or SB203580 (Catalog #72222), Vx702, and BIRB-796 (Catalog #72682), enhances the self-renewal of cord blood-derived hematopoietic stem cells (Baudet et al.).

CANCER RESEARCH
· By inhibiting p38 MAPK, which is highly expressed in human cancers, LY2228820 is potent and selective at inhibiting tumor growth in animal models of a variety of human cancers (Campbell et al.).
Alternative Names:
Ralimetinib Mesylate; LSN2322600
CAS Number:
862507-23-1
Chemical Formula:
C₂₄H₂₉FN₆ • 2CH₃SO₃H
Molecular Weight:
612.7 g/mol
Purity:
≥ 98%
Pathway:
p38 MAPK
Target:
p38 MAPK

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(5)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.